Selecting the Appropriate Patients for Proton Pump Inhibitor Discontinuation: A Teachable Moment his warfarin was replaced with aspirin 325 mg daily, which was continued for stroke prevention. He still used ibuprofen 200 mg 3 times weekly for back pain. h
RT @FarmaciaMT: 📝Teachable moment: desprescripción segura de IBPs. ⚠️Individualizar por paciente. 🤔¿Necesidad de una herramienta validada?…
RT @FarmaciaMT: 📝Teachable moment: desprescripción segura de IBPs. ⚠️Individualizar por paciente. 🤔¿Necesidad de una herramienta validada?…
RT @FarmaciaMT: 📝Teachable moment: desprescripción segura de IBPs. ⚠️Individualizar por paciente. 🤔¿Necesidad de una herramienta validada?…
RT @FarmaciaMT: 📝Teachable moment: desprescripción segura de IBPs. ⚠️Individualizar por paciente. 🤔¿Necesidad de una herramienta validada?…
RT @FarmaciaMT: 📝Teachable moment: desprescripción segura de IBPs. ⚠️Individualizar por paciente. 🤔¿Necesidad de una herramienta validada?…
📝Teachable moment: desprescripción segura de IBPs. ⚠️Individualizar por paciente. 🤔¿Necesidad de una herramienta validada? ⛔Mayor riesgo de sangrado por úlcera en: 📌AINES+AAS 📌Edad 📌Úlcera previa 📌Doble antiagregación plaquetaria 📌Sexo masculino https://t
RT @jcperezpons: Selecting the Appropriate Patients for Proton Pump Inhibitor Discontinuation https://t.co/F8eixsWJA8
Now that we use dual antiplatelet therapy for high risk #TIA and minor #stroke - Rx #Aspirin plus #Clopidogrel for #CHANCE #POINT or #Cilostazol for #CSPS - we shouldn’t forget about #PPI to prevent PUD by 79% @ImperialNHS @SomaBanerjee73 @Dheeraj_Kall #i
Selecting the Appropriate Patients for Proton Pump Inhibitor Discontinuation https://t.co/F8eixsWJA8
RT @JAMAInternalMed: #TeachableMoment: Identifying appropriate candidates for PPI discontinuation https://t.co/g2pu8znu85
RT @JAMAInternalMed: #TeachableMoment: Identifying appropriate candidates for PPI discontinuation https://t.co/g2pu8znu85
RT @JAMAInternalMed: #TeachableMoment: Identifying appropriate candidates for PPI discontinuation https://t.co/g2pu8znu85
#TeachableMoment: Identifying appropriate candidates for PPI discontinuation https://t.co/g2pu8znu85
RT @virgilioh: De un lado está la polifarmacia (inapropiada) y del otro está el retirar fármacos nada más por que sí. En medio tiene que…
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @OptimisingRxUse: This is why #Deprescribing needs to be patient-focused, considering individual benefits and risks I ❤️ the table of R…
RT @OptimisingRxUse: This is why #Deprescribing needs to be patient-focused, considering individual benefits and risks I ❤️ the table of R…
RT @OptimisingRxUse: This is why #Deprescribing needs to be patient-focused, considering individual benefits and risks I ❤️ the table of R…
This is why #Deprescribing needs to be patient-focused, considering individual benefits and risks I ❤️ the table of RRs for GI bleeding: this could make patient conversations easier. @SaferMedsNL @DeprescribeNet @Deprescribing @DeprescribeAU https://t.co
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
De un lado está la polifarmacia (inapropiada) y del otro está el retirar fármacos nada más por que sí. En medio tiene que estar nuestro juicio clínico y análisis caso a caso. La #deprescripción siempre debe llevar un razonamiento https://t.co/19mvmnLqe
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @DeprescribeAU: As with prescribing decisions #deprescribing decisions should consider the benefits and harms in the individual. A #medi…
RT @Roxytonin: You might think that stopping PPIs for this chap was a bad decision but it's a lovely reminder that deprescribing carries it…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
Selecting the Appropriate Patients for Proton Pump Inhibitor Discontinuation https://t.co/lbpkvJu6AN
RT @Roxytonin: You might think that stopping PPIs for this chap was a bad decision but it's a lovely reminder that deprescribing carries it…
Great #emergencymedicine case highlighting risks of aspirin, NSAIDS, anticoagulants and indications for PPIs. Also, look at the RR of bleeding for high dose NSAIDS!#ibuprofen800mg #justdont https://t.co/Ux7i03svTw
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
As with prescribing decisions #deprescribing decisions should consider the benefits and harms in the individual. A #medication can be #overused on a population level but still appropriate in an individual - this is a great case study which illustrates this
RT @Deprescribing: Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions abou…
Thanks Mike! We developed our Bruyère evidence-based PPI deprescribing guideline to help people make good decisions about WHEN and how to reduce or stop PPI. https://t.co/l1h3kvgLT6 This patient’s situation fits exclusion criteria. How do we help people us
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
RT @MikeSteinman: Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary m…
Sometimes less is... less. Great case study in over-aggressive #deprescribing. Reducing inappropriate and unnecessary meds can be very helpful but need to individualize and avoid reflexive medicine. https://t.co/YpD1rva0Lo @Deprescribing @DeprescribeNet
RT @Roxytonin: You might think that stopping PPIs for this chap was a bad decision but it's a lovely reminder that deprescribing carries it…
RT @Roxytonin: You might think that stopping PPIs for this chap was a bad decision but it's a lovely reminder that deprescribing carries it…
You might think that stopping PPIs for this chap was a bad decision but it's a lovely reminder that deprescribing carries its own risks. And it contains this beautiful quote: https://t.co/zQhZ2T719s https://t.co/xDiUy0Xhbl
Omeprazole is one of the most prescribed drugs in Brazil. Sometimes patients 'wins' it because 'take a lot of medicines'. Discuss the criterias for discontinuation is important, as well as the adverse events!